

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM620563

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, as Collateral Agent		01/13/2021	Bank: SWITZERLAND

RECEIVING PARTY DATA

Name:	JAGUAR HOLDING COMPANY I
Street Address:	929 North Front Street
City:	Wilmington
State/Country:	NORTH CAROLINA
Postal Code:	28401
Entity Type:	Corporation: DELAWARE
Name:	Jaguar Holding Company II
Street Address:	929 North Front Street
City:	Wilmington
State/Country:	NORTH CAROLINA
Postal Code:	28401
Entity Type:	Corporation: DELAWARE
Name:	Pharmaceutical Product Development, LLC
Street Address:	929 North Front Street
City:	Wilmington
State/Country:	NORTH CAROLINA
Postal Code:	28401
Entity Type:	Limited Liability Company: DELAWARE

PROPERTY NUMBERS Total: 45

Property Type	Number	Word Mark
Registration Number:	3637316	CLINICAL RESEARCH ADVANTAGE
Registration Number:	3597155	CLINICAL RESEARCH ADVANTAGE
Registration Number:	3431297	CNS
Registration Number:	3431298	CNS
Registration Number:	3431299	CNS
Registration Number:	3431300	CNS

TRADEMARK

Property Type	Number	Word Mark
Registration Number:	3966684	CNS COMPREHENSIVE NEUROSCIENCE
Registration Number:	3962188	CNS COMPREHENSIVE NEUROSCIENCE
Registration Number:	3962189	CNS COMPREHENSIVE NEUROSCIENCE
Registration Number:	3962190	CNS COMPREHENSIVE NEUROSCIENCE
Registration Number:	3966685	CNS COMPREHENSIVE NEUROSCIENCE
Registration Number:	4084213	CNS COMPREHENSIVE NEUROSCIENCE
Registration Number:	3449533	CNS COMPREHENSIVE NEUROSCIENCE
Registration Number:	3449534	CNS COMPREHENSIVE NEUROSCIENCE
Registration Number:	3449535	CNS COMPREHENSIVE NEUROSCIENCE
Registration Number:	3449536	CNS COMPREHENSIVE NEUROSCIENCE
Registration Number:	4156802	COMPREHENSIVE CLINICAL DEVELOPMENT
Registration Number:	4156803	COMPREHENSIVE CLINICAL DEVELOPMENT
Registration Number:	4156804	COMPREHENSIVE CLINICAL DEVELOPMENT
Registration Number:	4155886	COMPREHENSIVE CLINICAL DEVELOPMENT
Registration Number:	4148011	COMPREHENSIVE CLINICAL DEVELOPMENT
Registration Number:	4155887	COMPREHENSIVE CLINICAL DEVELOPMENT
Registration Number:	3500478	COMPREHENSIVE NEUROSCIENCE
Registration Number:	3500479	COMPREHENSIVE NEUROSCIENCE
Registration Number:	3500480	COMPREHENSIVE NEUROSCIENCE
Registration Number:	3500781	OMAC CONNECT AND PACK
Registration Number:	3500482	COMPREHENSIVE NEUROSCIENCE
Registration Number:	3500483	COMPREHENSIVE NEUROSCIENCE
Registration Number:	2511395	RADIANT RESEARCH
Registration Number:	2136203	CG++
Registration Number:	2084758	CROSSGRAPHS
Registration Number:	2435414	PPD
Registration Number:	2332213	PPD
Registration Number:	2644316	PPD QUERYDIRECT
Registration Number:	2179522	TABLETRANS
Registration Number:	4573756	PRECLARUS
Registration Number:	3971039	ACURIAN RECRUITMENT MANAGER
Registration Number:	3723631	YOUR PATIENTS HOLD THE PROMISE FOR TOMOR
Registration Number:	3819261	CLICK IT FORWARD
Registration Number:	2697439	ACURIAN
Registration Number:	2566246	ACURIAN
Registration Number:	4411824	ACURIAN HEALTH
Registration Number:	4429550	
Registration Number:	4621574	ACURIAN RETENTION MANAGER

Property Type	Number	Word Mark
Serial Number:	86303607	TRIMENTUM

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 800-494-5225

Email: ipteam@cogencyglobal.com

Correspondent Name: Stewart Walsh

Address Line 1: 1025 Vermont Ave NW, Suite 1130

Address Line 2: COGENCY GLOBAL Inc.

Address Line 4: Washington, D.C. 20005

ATTORNEY DOCKET NUMBER:	1315278Â TM A
NAME OF SUBMITTER:	Hannah Adkins
SIGNATURE:	/Hannah Adkins/
DATE SIGNED:	01/15/2021

Total Attachments: 5

source=A PPD - Trademark Release RF 5615.0526 (Executed)#page2.tif

source=A PPD - Trademark Release RF 5615.0526 (Executed)#page3.tif

source=A PPD - Trademark Release RF 5615.0526 (Executed)#page4.tif

source=A PPD - Trademark Release RF 5615.0526 (Executed)#page5.tif

source=A PPD - Trademark Release RF 5615.0526 (Executed)#page6.tif

RELEASE OF TRADEMARK SECURITY INTERESTS dated as of January 13, 2021 (this “Release”), by CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, as collateral agent (the “Collateral Agent”) for the Secured Parties, in favor of the Grantors (defined below). Capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Credit Agreement, the Security Agreement or the IP Security Agreement, as applicable, referred to below.

A. Reference is made to (i) the Credit Agreement dated as of August 18, 2015 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), among Jaguar Holding Company I, a Delaware corporation (“Holdings”), Jaguar Holding Company II, a Delaware corporation (the “Parent Borrower”), Pharmaceutical Product Development, LLC, a Delaware limited liability company (the “Subsidiary Borrower”), the Lenders, the L/C Issuers and the Collateral Agent, (ii) the Security Agreement dated as of August 18, 2015 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”), among the Grantors from time to time party thereto and the Collateral Agent and (iii) the Intellectual Property Security Agreement dated as of August 18, 2015, among the Grantors listed therein and the Collateral Agent (as amended, amended and restated, supplemented or otherwise modified from time to time, the “IP Security Agreement”) (such documents set forth in clauses (i) through (iii), the “Security Documents”).

B. Pursuant to the Security Documents, the Persons listed on Schedule I hereto (the “Grantors”) collaterally assigned, pledged and granted to the Collateral Agent, for the benefit of the Secured Parties, a security interest in, among other property, the Trademark Collateral (as hereinafter defined), which security interest was recorded with the United States Patent & Trademark Office on September 2, 2015 at Reel/Frame 5615/0526.

C. Pursuant to the Payoff Letter dated as of January 12, 2021, among Holdings, the Parent Borrower, the Subsidiary Borrower and the Collateral Agent, the Collateral Agent agreed to release any and all security interests it may have in the Trademark Collateral pursuant to the Security Documents.

Accordingly, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent does hereby release, relinquish and discharge its security interest it has in and to all of the following in each case to the extent created, granted or otherwise established under any Security Document (the “Trademark Collateral”):

With respect to each Grantor, all of such Grantor’s right title and interest in and to the following:

(i) the trademarks and service marks owned by such Grantor, including those of such Grantor set forth on Schedule I hereto, together with the goodwill symbolized thereby;

(ii) all reissues, divisionals, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the foregoing, all rights in the foregoing provided by international treaties or conventions, all rights corresponding thereto throughout the world and all other rights of any kind whatsoever of such Grantor accruing thereunder or pertaining thereto;

(iii) any and all claims for damages and injunctive relief for past, present and future infringement, dilution, misappropriation, violation, misuse or breach with respect to any of the foregoing, with the right, but not the obligation, to sue for and collect, or otherwise recover, such damages; and

(iv) any and all proceeds of, collateral for, income, royalties and other payments now or hereafter due and payable with respect to, and supporting obligations relating to, any and all of the Trademark Collateral of or arising from any of the foregoing.

The Collateral Agent hereby re-assigns to each Grantor any right, title or interest it may have in the Trademark Collateral of such Grantor, without representation or warranty of any kind. The Collateral Agent authorizes each Grantor (or their designee, or any person or entity hereafter having any right title or interest in the Trademark Collateral of such Grantor) to make filings with the United States Patent and Trademark Office and other necessary filings, in each case at the expense of such Grantor, to evidence the release and termination of the Collateral Agent's security interests in the Trademark Collateral of such Grantor.


Sections 4 and 6 of the IP Security Agreement are incorporated herein by reference, *mutatis mutandis*.

[The remainder of this page intentionally left blank]

IN WITNESS WHEREOF, the Collateral Agent has caused this Release to be duly executed as of the day and year first above written.

CREDIT SUISSE AG, CAYMAN ISLANDS
BRANCH, as Collateral Agent,


By



Name: Whitney Gaston

Title: Authorized Signatory

By



Name: Komal Shah


Title: Authorized Signatory

Schedule I

Trademarks

Registered Trademarks

Owner	Mark	Registration Number	Expiration Date
Clinical Research Advantage, Inc.	CLINICAL RESEARCH ADVANTAGE	3637316	Jun. 16, 2019
Clinical Research Advantage, Inc.	CLINICAL RESEARCH ADVANTAGE	3597155	Mar. 31, 2019
CNS Research Science, Inc.	CNS	3431297	May 20, 2018
CNS Research Science, Inc.	CNS	3431298	May 20, 2018
CNS Research Science, Inc.	CNS	3431299	May 20, 2018
CNS Research Science, Inc.	CNS	3431300	May 20, 2018
CNS Research Science, Inc.	CNS COMPREHENSIVE NEUROSCIENCE	3966684	Aug. 24, 2021
CNS Research Science, Inc.	CNS COMPREHENSIVE NEUROSCIENCE	3962188	May 17, 2021
CNS Research Science, Inc.	CNS COMPREHENSIVE NEUROSCIENCE	3962189	May 17, 2021
CNS Research Science, Inc.	CNS COMPREHENSIVE NEUROSCIENCE	3962190	May 17, 2021
CNS Research Science, Inc.	CNS COMPREHENSIVE NEUROSCIENCE	3966685	May 24, 2021
CNS Research Science, Inc.	CNS COMPREHENSIVE NEUROSCIENCE	4084213	Jan. 10, 2022
CNS Research Science, Inc.	CNS COMPREHENSIVE NEUROSCIENCE	3449533	Jun. 17, 2018
CNS Research Science, Inc.	CNS COMPREHENSIVE NEUROSCIENCE	3449534	Jun. 17, 2018
CNS Research Science, Inc.	CNS COMPREHENSIVE NEUROSCIENCE	3449535	Jun. 17, 2018
CNS Research Science, Inc.	CNS COMPREHENSIVE NEUROSCIENCE	3449536	Jun. 17, 2018
CNS Research Science, Inc.	COMPREHENSIVE CLINICAL DEVELOPMENT	4156802	Jun. 12, 2022
CNS Research Science, Inc.	COMPREHENSIVE CLINICAL DEVELOPMENT	4156803	Jun. 12, 2022
CNS Research Science, Inc.	COMPREHENSIVE CLINICAL DEVELOPMENT	4156804	Jun. 12, 2022
CNS Research Science, Inc.	COMPREHENSIVE CLINICAL DEVELOPMENT	4155886	Jun. 5, 2022
CNS Research Science, Inc.	COMPREHENSIVE CLINICAL DEVELOPMENT	4148011	May 22, 2022
CNS Research Science, Inc.	COMPREHENSIVE CLINICAL DEVELOPMENT	4155887	Jun. 5, 2022

Owner	Mark	Registration Number	Expiration Date
CNS Research Science, Inc.	COMPREHENSIVE NEUROSCIENCE	3500478	Sep. 9, 2018
CNS Research Science, Inc.	COMPREHENSIVE NEUROSCIENCE	3500479	Sep. 9, 2018
CNS Research Science, Inc.	COMPREHENSIVE NEUROSCIENCE	3500480	Sep. 9, 2018
CNS Research Science, Inc.	COMPREHENSIVE NEUROSCIENCE	3500781	Sep. 9, 2018
CNS Research Science, Inc.	COMPREHENSIVE NEUROSCIENCE	3500482	Sep. 9, 2018
CNS Research Science, Inc.	COMPREHENSIVE NEUROSCIENCE	3500483	Sep. 8, 2018
Radiant Research, Inc.	RADIANT RESEARCH	2511395	Nov. 27, 2021
Pharmaco Investments, Inc.	"CG++"	2,136,203	Feb. 10, 2018
Pharmaco Investments, Inc.	"CROSSGRAPHS"	2,084,758	July 29, 2017
Pharmaco Investments, Inc.	"PPD" (Word Mark)	2,435,414	Mar. 13, 2021
Pharmaco Investments, Inc.	"PPD"	2,332,213	Mar. 21, 2020
Pharmaco Investments, Inc.	"PPD QUERYDIRECT"	2,644,316	Oct. 29, 2022
Pharmaco Investments, Inc.	"TABLETRANS"	2,179,522	Aug. 4, 2018
Pharmaco Investments, Inc.	"PRECLARUS"	4,573,756	Jul. 22, 2024
Acurian, Inc.	"ACURIAN RECRUITMENT MANAGER"	3,971,039	May 31, 2021
Acurian, Inc.	"YOUR PATIENTS HOLD THE PROMISE FOR TOMORROW'S CURES"	3,723,631	Dec. 8, 2019
Acurian, Inc.	"CLICK IT FORWARD"	3,819,261	Jul. 13, 2020
Acurian, Inc.	"ACURIAN" (Plus Design)	2,697,439	Mar. 18 2023
Acurian, Inc.	"ACURIAN"	2,566,246	Apr. 30, 2022
Acurian, Inc.	"ACURIAN HEALTH"	4,411,824	Oct. 1, 2023
Acurian, Inc.		4,429,550	Nov. 5, 2023
Acurian, Inc.	"ACURIAN RETENTION MANAGER"	4,621,574	Oct. 14, 2024

Trademark Applications

Owner	Mark	Application Number	Expiration Date
Pharmaco Investments, Inc.	"TRIMENTUM"	86303607	N/A